{"id":1009579,"date":"2026-10-13T10:58:46","date_gmt":"2026-10-13T14:58:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/"},"modified":"2026-10-13T10:58:46","modified_gmt":"2026-10-13T14:58:46","slug":"mbx-biosciences-to-participate-in-upcoming-november-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/","title":{"rendered":"MBX Biosciences to Participate in Upcoming November Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CARMEL, Ind. and BURLINGTON, Mass., Oct.  13, 2026  (GLOBE NEWSWIRE) &#8212; MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:<\/p>\n<p>\n        <strong>Guggenheim 3rd Annual Healthcare Innovation Conference<\/strong><br \/>\n        <br \/>Date: Tuesday, November 10, 2026<br \/>Format: Fireside Chat and 1&#215;1 meetings<br \/>Time: 11:00 \u2013 11:25 a.m. EST <br \/>Location: Boston, MA<\/p>\n<p>\n        <strong>UBS Global Biopharma Conference<\/strong><br \/>\n        <br \/>Date: Tuesday, November 17, 2026<br \/>Format: Fireside Chat and 1&#215;1 meetings<br \/>Time: 8:00 \u2013 8:30 a.m. GMT <br \/>Location: London, UK<\/p>\n<p>\n        <strong>Jefferies Global Healthcare Conference<\/strong><br \/>\n        <br \/>Date: Wednesday, November 18, 2026<br \/>Format: Fireside Chat and 1&#215;1 meetings<br \/>Time: 4:00 \u2013 4:25 p.m. GMT <br \/>Location: London, UK<\/p>\n<p>The live webcasts can be accessed in the events section of the MBX Biosciences website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z-rIpy0KW2U2Gsqih43CnTcscWNj6XnJZGYa7BVTfbWazYlzWm18obwkVcNGSjnc8yiQXMwqBiiiEvsFmOMtaL-koaPSH02WpqdZlrVADpGu9xT3626hzJ5hwP80pWEnEbD-5_LWvxurrdduaAjsIJKi5D0wx7eUBKBe02Z8I8QN2X00MZORLDgAxQl5Ct723C_MoWs89FBGi8I7miLv5h-WY_kL1DEBclbabBok7ECU9z15bkJAhMHuJoBdAPkHfh8VxzCe1jWWLkpLVjCMm8Rb6G-hc8JwyNld6be1B2EYfALrpGOpar2btOEmMEppGDXQfbo49sAq0KqWFYoh_cpZYIld0jSdgF3JtyPbRebbQJrV-tRgINC_P8-DC3XPHS2UvWBA1Sa4Wt6UN80IZw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.mbxbio.com\/news-events\/events<\/a>. Access to the webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company\u2019s website for approximately 90 days.<\/p>\n<p>\n        <strong>About\u00a0MBX Biosciences<\/strong><br \/>\n        <br \/>MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP\u2122 platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company\u2019s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase 3; and an obesity portfolio that includes MBX 4291 in Phase 1, and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4KgRkfNkFO7GDoZPK_80pLHubzr1QS8tDgA3gng8uHNP8_Phri9KcFEmIP0x5llIuHrfPPVq2ewZeWTer8RSJA==\" rel=\"nofollow\" target=\"_blank\">www.mbxbio.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rU153lCyn1aK0X9p4UvVS4QtpEOvC6ERl2dxom9SF04nS8nfnOQcZ0sAVnZmfczMtWcP0El6RSfEHXNrQg2yS-hH5HZTg4JrOozdMueioGrgAPGCWMJF7tOw9lurexgUP2pXeEQjDuziiyeG0aL_TQ17nVvBIX745cJSiX3q73ZFkUNWXMRCqucU0xlBEtL7ssq32xg5Mgsqab5c7CELyns4M62JFJXhExKcogDyVR1rkOqZn4Hwrlke3pmrT_5-I8Fh2qnmo7nNZSZVi0KBZg==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A0uSYsTBb9JvpSr6s1TFWo9RCktI9lDwD-DLIRk5zc2BHx9jN_IMWxRZw_oU0SO1OUI1ciOkxed06_3aSztjqzx7R9qQYnVCVvjSStvNr0gwVXCjSY6vaFeWZUU784Ha9Ow2Da0T6y65cDgS2mUuoAcbssm0IMK56YqSGrMBRgFeHBH-hdhENkxUPncgjz5O\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p><strong>Media Contact:<\/strong><br \/>George Shea<br \/>We. Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4tUVEt9U-f5wmN8Lr7CiatGmKY35QhM0CnYbHMuXi35-NWdgh9ExiqYcHOZQVRRnJJbw2wKvU7be5XWIveH3N3aP0P1rYfXBdb6JB5mNf8B6DoqTY5SCPHwPdCa7V7Oz\" rel=\"nofollow\" target=\"_blank\">gshea@wecommunications.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Pete De Spain<br \/>MBX Biosciences<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=06kmsrH0AqnaWR3dPWodtH-747n9A9GY1uJc6sJispat6FDaq58WD276pbpvVASeRPc-rjBJLFin4ZTD_lrKYRqlgN87ewh5t-4L-X4SxNU=\" rel=\"nofollow\" target=\"_blank\">pdespain@mbxbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWIwMjg1OTktOWE4ZS00MTQ5LWI2M2QtM2Y2Mzg0YjBiOTNhLTEyNTY5MjctMjAyNi0xMC0xMy1lbg==\/tiny\/MBX-Biosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) &#8212; MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Date: Tuesday, November 10, 2026Format: Fireside Chat and 1&#215;1 meetingsTime: 11:00 \u2013 11:25 a.m. EST Location: Boston, MA UBS Global Biopharma Conference Date: Tuesday, November 17, 2026Format: Fireside Chat and 1&#215;1 meetingsTime: 8:00 \u2013 8:30 a.m. GMT Location: London, UK Jefferies Global Healthcare Conference Date: Wednesday, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MBX Biosciences to Participate in Upcoming November Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1009579","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MBX Biosciences to Participate in Upcoming November Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MBX Biosciences to Participate in Upcoming November Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) &#8212; MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Date: Tuesday, November 10, 2026Format: Fireside Chat and 1&#215;1 meetingsTime: 11:00 \u2013 11:25 a.m. EST Location: Boston, MA UBS Global Biopharma Conference Date: Tuesday, November 17, 2026Format: Fireside Chat and 1&#215;1 meetingsTime: 8:00 \u2013 8:30 a.m. GMT Location: London, UK Jefferies Global Healthcare Conference Date: Wednesday, &hellip; Continue reading &quot;MBX Biosciences to Participate in Upcoming November Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-13T14:58:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MBX Biosciences to Participate in Upcoming November Investor Conferences\",\"datePublished\":\"2026-10-13T14:58:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/\"},\"wordCount\":336,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/\",\"name\":\"MBX Biosciences to Participate in Upcoming November Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ=\",\"datePublished\":\"2026-10-13T14:58:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MBX Biosciences to Participate in Upcoming November Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MBX Biosciences to Participate in Upcoming November Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"MBX Biosciences to Participate in Upcoming November Investor Conferences - Market Newsdesk","og_description":"CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) &#8212; MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Date: Tuesday, November 10, 2026Format: Fireside Chat and 1&#215;1 meetingsTime: 11:00 \u2013 11:25 a.m. EST Location: Boston, MA UBS Global Biopharma Conference Date: Tuesday, November 17, 2026Format: Fireside Chat and 1&#215;1 meetingsTime: 8:00 \u2013 8:30 a.m. GMT Location: London, UK Jefferies Global Healthcare Conference Date: Wednesday, &hellip; Continue reading \"MBX Biosciences to Participate in Upcoming November Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-13T14:58:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MBX Biosciences to Participate in Upcoming November Investor Conferences","datePublished":"2026-10-13T14:58:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/"},"wordCount":336,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/","name":"MBX Biosciences to Participate in Upcoming November Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ=","datePublished":"2026-10-13T14:58:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0Mzk3OSM3ODkxMDA2IzIyNDUzNzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MBX Biosciences to Participate in Upcoming November Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1009579"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009579\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1009579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1009579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1009579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}